The Potential Role of Inflammation in Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD) is the most common form of dementia, and causes a progressive decline in memory, language, executive and visuospatial function, personality and behaviour.1 For many years, there have been only four approved medications to improve cognition in patients with AD, but these only address the symptoms, and do not affect the course of the underlying disease.2–5 In an expert interview, Professor Jeffrey Cummings discusses the role of inflammation in AD and the upcoming GREEN MEMORY study (NCT04520412), a global randomized clinical trial investigating the use of GV-971 (sodium oligomannate) for the treatment of AD.6,7.